Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial

Lack of consensus for first‐line marginal zone lymphoma (MZL) treatment and toxicities associated with currently available systemic therapies have inspired evaluation of immunotherapeutic agents yielding robust outcomes with improved tolerability. We previously reported durable efficacy with first‐l...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Haematol
Auteurs principaux: Becnel, Melody R., Nastoupil, Loretta J., Samaniego, Felipe, Davis, Richard E., You, M. J., Green, Michael, Hagemeister, Fredrick B., Fanale, Michelle A., Fayad, Luis E., Westin, Jason R., Wang, Michael, Oki, Yasuhiro, Forbes, Sheryl G., Feng, Lei, Neelapu, Sattva S., Fowler, Nathan H.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Haematological Malignancy
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6619290/
https://ncbi.nlm.nih.gov/pubmed/30919940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15843
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires